Abstract Body

Background

Glucagon-like peptide-1 (GLP-1) receptor agonists (RA) have been shown to have marked efficacy in improving blood glucose and reducing weight among individuals in randomized trials. However, real-world data on weight changes after GLP-1 RA initiation among people with HIV remain limited.

Methods

Using patient-level data from 82 sites in the U.S. National COVID Cohort Collaborative (N3C), a nationally-sampled electronic health records repository, we conducted a retrospective analysis with all patients with HIV receiving GLP-1 RA (i.e., tirzepatide or semaglutide injection), sodium-glucose cotransporter-2 (SGLT-2, e.g.,empagliflozin), or metformin between January 1, 2018 and November 2, 2023, regardless of indication, with the metformin only group as the reference. Changes in weight per month were modeled since baseline weight at drug initiation (+/- 3 months) up to 12 months after treatment. We used mixed effect linear regression, stratified by sex. Models controlled for age, race/ethnicity, baseline weight, height, diabetes status (pre-diabetes, type I, type II diabetes, or none), and Charlson Comorbidity Index.  

Results

Of 456,558 patients who received GLP-1 RA, metformin, or SGLT-2, 3,955 were people with HIV (PWH). At baseline, the median age of PWH was 59 years (IQR 52–65), with 59% male, 38% white, 42% Black, and 15% Latinx. Among women with HIV, those who received tirzepatide or semaglutide experienced faster weight loss compared to those who only received metformin, with an average of 1.12 kg/month (95% CI: -0.76, -1.49) and 0.87 kg/month (95% CI: -0.54, -1.19), respectively (Figure). No significant difference in weight loss was observed among men with HIV when comparing metformin to GLP-1 RA during the first 12 months. However, men receiving semaglutide had a slightly faster weight loss rate of 0.07 kg/month, though this was not statistically significant.

Conclusions

This real-world data suggests that among women with HIV, use of semaglutide or tirzepatide is associated with greater weight loss than use of metformin in the first 12 months. Differences in weight change is less pronounced among men with HIV. Additional work needs to address the sex differences and underlying mechanisms of weight changes after using weight loss drugs among PWH.